AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Molecular Templates ... toxin bodies (ETBs), provided a corporate update and outlined expected 2022 milestones. “2021 was a year of growth ...

Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Management implementing price increases in Display Technologies and expects to deliver segment net income of $900 million to $950 million in 2025, and to maintain net income margin of 25% In ...

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the second quarter ended June 30, 2024 and provided a regulatory and corporate update. “The FDA acceptance of ...